FIELD: medicine.
SUBSTANCE: invention relates to an in vitro method for therapy follow-up in patients being suspected of having sepsis. Method comprises: concentration of mature adrenomedullin (ADM) (1-52-amide) and/or mature ADM 1-52-Gly in a sample of bodily fluid of said septic patient is determined, using an assay comprising two binders that are selected from the group comprising an anti-ADM antibody and/or an anti-ADM antibody fragment, that bind to two different regions within the region of mature ADM 1-52-amide and/ or ADM 1-52-Gly, that is amino acid 21-52-amide (SEQ ID No. 1) or amino acid 21-52-Gly (SEQ ID No. 2) respectively. Each of said regions contains at least 4 or 5 amino acids, wherein follow-up therapy is carried out by comparing a certain concentration of mature ADM 1-52 amide and / or mature ADM 1-52-Gly with a threshold value, where the concentration values of the mature ADM 1-52 amide and / or the mature ADM 1-52-Gly above the threshold value are indicative of a patient that is not or badly responding to therapy and whereas values below said threshold are indicative of a patient responding to therapy. Invention relates to a combination of two binders for determining mature ADM 1-52 amide and / or ADM 1-52-Gly in a sample, which bind to two different regions within the region of the mature ADM 1-52 amide and / or ADM 1-52-Gly, that is amino acid 21-52-amide (SEQ ID No. 1) or the amino acid 21-52-Gly mature adromedullin (SEQ ID NO. 2) respectively, wherein each of said regions comprises at least 4 or 5 amino acids, and where the immunoassay is not a sandwich assay, performed manually with a tube coated with acridinium ester.
EFFECT: invention also relates to a kit for determining mature ADM 1-52 amide and/or ADM 1-52-Gly in a sample containing a combination of said two binders.
25 cl, 6 ex, 6 tbl, 11 dwg
